Skip to main content
OpenTrials
Completed

NCT Number: NCT03757143

Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure

Short peripheral intravenous catheters (PVC) are the most frequently used invasive medical devices in hospitals. Unfortunately, PVCs often fail before the end of treatment due to the occurrence of complications, which can be mechanical, vascular or infectious. Complications lead to infusion failure and device replacement, which results in interrupted therapy, pain associated with resiting and increased health care costs for resources and staff time. Catheter related bloodstream infections (CR-BSIs) prolong hospitalization and increase treatment costs and mortality.

Prevention of these complications is based on the respect of hygiene rules and the use of bio-compatible catheters. The choice of the antiseptic solution for skin disinfection is key. Similarly, the use of new technologies such as catheters designed to minimize blood exposure, zero-reflux needleless-connectors, disinfecting caps, and flushing PVCs before and after each medication administration to maintain catheter patency are of theoretical interest, but little scientific data support their use in routine.

The primary objectives of this study are, first, to demonstrate that skin preparation with 2% chlorhexidine (CHG)-70% isopropanol decreases the risk of PVC colonization compared to skin preparation with 5% povidone iodine (PVI)-69% ethanol. Second, to demonstrate that use of a bundle of technologies including a new PVC, zero-reflux needless-connectors, disinfecting caps, and single-use prefilled flush syringes extends the time between catheter insertion and catheter failure.

The secondary objectives are to compare between the four study group incidence of phlebitis, accidental catheter removal, infiltration, catheter occlusion, CR-BSI, local infection, all-cause bloodstream infections, catheter colonization, duration of catheter remaining in place without complication, length of hospital stay, safety and patient satisfaction.

The CLEAN 3 study is an open-label, single centre, investigator-initiated, randomised, four-parallel group, two-by-two factorial trial. Patients requiring PVC for an expected 48 h will be randomised in one of four groups according to skin disinfection method and type of devices used. Randomization will be carried out through a secure web-based randomization system. Inclusions are expected to begin in January 2019 and continue until July 2019, once the number of catheters required has been reached.

Patients will be enrolled at the Emergency department of the Poitiers University Hospital before being hospitalised in one of five wards (neurology, neurology, pneumology, internal medicine and downstream emergency unit).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intravascular-catheter Colonization Catheter Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Hospital of Poitiers

Poitiers, 86021, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (age ≥ 18 years) patients,
  • Having clinical indication for placement of a single PVC for at least 48 hours (no minimum port access during the study duration),
  • Willing and able to provide informed consent.

Exclusion criteria

  • Known allergies to CHG, PVI, isopropanol or ethanol,
  • Participation to another clinical trial aimed at reducing PVC complications,
  • Suspicion of bloodstream infection at catheter insertion,
  • Skin injury a catheter insertion site increasing the risk of catheter infection,
  • PVC inserted extremely urgently, making it impossible to comply with the protocol,
  • Intravascular catheter in place within the last 2 days, or within the last 2 weeks and with local signs of catheter complication,
  • Difficult catheter insertion suspected (obesity, known IV drug users, non-visible venous network after placement of a tourniquet...),
  • Patients already enrolled in this study,
  • Terminal or moribund patient not expected to live more than one week,
  • Patients not benefiting from a Social Security scheme or not benefiting from it through a third party,
  • Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
  • Pregnant or breastfeeding women
  • Women at age to procreate and not using effective contraception

Treatment and study plan

Povidone-Iodine-Alcohol

Drug

Povidone-Iodine-Alcohol will be used to disinfect the skin

Chlorhexidine-Alcohol

Drug

Chlorhexidine-Alcohol will be used to disinfect the skin

Insyte Autoguard BC Winged

Device

Pose of Insyte Autoguard BC Winged

Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes

Device

Pose of Nexiva single port catheter

Primary outcomes

  1. Incidence of catheter-related infectious complications

    Time frame: 8 days

    Incidence of catheter-related infectious complications, and include catheter colonisation, local infection and CR-BSI

  2. Time between catheter insertion and catheter failure

    Time frame: 8 days

    Time between catheter insertion and catheter failure: defined as any premature removal of PVC before end of treatment, other than for routine replacement, and includes phlebitis, infiltration, occlusion, accidental catheter removal, local infection and CR-BSI whichever occurred first

Secondary outcomes

  1. Number of phlebitis

    Time frame: 8 days

    Number of phlebitis defined as two or more of the following present simultaneously: (1) patient-reported pain or tenderness (on questioning, then palpation by the research nurse) with a severity of two or more on a ten-point scale; (2) erythema extending at least 1 cm from the insertion site; (3) swelling, extending at least 1 cm from the insertion site; (4) purulent discharge; or (5) palpable venous cord beyond the intravenous catheter tip

  2. Number of accidental catheter removal

    Time frame: 8 days

  3. Number of infiltration

    Time frame: 8 days

    Number of infiltration, defined as the infusion of non-blistering drug leaking through the normal vascular channel and resulting in the swelling of tissue peripheral to the puncture site

  4. Number of catheter occlusion

    Time frame: 8 days

    Number of catheter occlusion defined as the inability of the catheter to flush (not able to intravenously inject 1ml of normal saline within 30 s)

  5. Number of CR-BSI

    Time frame: 8 days

    Number of CR-BSI, defined as (1) at least one positive blood culture from a peripheral vein and (2) clinical signs of infection (ie, fever [body temperature >38°5], hypothermia [body temperature <36°5], chills, or hypotension [Systolic blood pressure <90 mm Hg]) and (3) no other apparent source for the bloodstream infection except the PVC (in situ within 48 h of the bloodstream infection); and (4) a colonized intravenous catheter tip culture with the same organism (same species) as identified in the blood. For commensal micro-organisms (coagulase-negative staphylococci, Corynebacterium spp. [except C. jeikeium], Lactobacillus spp., Bacillus spp. and Propionibacterium spp., or viridans group Streptococcus isolates and C. perfringens) at least two positive blood cultures will be required.

  6. Number of local infection

    Time frame: 8 days

    Number of local infection, defined as organisms grown from purulent discharge with no evidence of associated bloodstream infection

  7. Number of all-cause bloodstream infections

    Time frame: 8 days

    Number of all-cause bloodstream infections, defined as any positive blood culture drawn from a peripheral vein while intravenous catheter in situ or for 48 h after removal. For commensal micro-organisms (coagulase-negative staphylococci, Corynebacterium spp. [except C. jeikeium], Lactobacillus spp., Bacillus spp. and Propionibacterium spp., or viridans group Streptococcus isolates and C. perfringens) at least two positive blood cultures will be required

  8. Number of catheter colonization

    Time frame: 8 days

    Number of catheter colonization defined as the culture of intravascular catheter tip showing at least 1000 colony-forming units per ml (cfu/ml).

  9. Number of pathogens involved in catheter colonization, local infections, CR-BSI and all-cause bloodstream infections

    Time frame: 8 days

  10. Number of days the catheter remaining in place without complication

    Time frame: 8 days

  11. Length of Hospital stay censored at day 28

    Time frame: 28 days

  12. Incidence of local and systemic side effects possibly linked to antiseptic use

    Time frame: 8 days

  13. Patient's evaluation of the pain at the insertion of the catheter using visual analogue scale (VAS)

    Time frame: 8 days

    Visual analogue scale is increased from 0 to 10, 0 is the better outcome (no pain) and 10 is the worse outcome

  14. Patient's satisfaction at catheter removal using visual analogue scale (VAS)

    Time frame: 8 days

    Visual analogue scale is increased from 0 to 10, 0 is the worse outcome (no satisfaction) and 10 is the better outcome

  15. Evaluation impact of venous line on patients' mobility at catheter removal using visual analogue scale

    Time frame: 8 days

    Visual analogue scale is increased from 0 to 10, 0 is the better outcome (no impact of patients'mobility) and 10 is the worse outcome

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Official study title

Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled, Two-by-two Factorial Trial

Acronym: CLEAN3

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Nov 28, 2018
Registry last updated
Oct 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.